Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rapport Therapeutics, Inc. ( (RAPP) ) just unveiled an update.
On September 9, 2025, Rapport Therapeutics, Inc. entered into an underwriting agreement with several financial institutions for a public offering of 9,615,385 shares of its common stock at $26.00 per share, potentially raising approximately $234.7 million. The proceeds are intended to fund clinical trials, research, and general corporate purposes, with the offering expected to close around September 11, 2025, pending customary conditions.
The most recent analyst rating on (RAPP) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Rapport Therapeutics, Inc. stock, see the RAPP Stock Forecast page.
Spark’s Take on RAPP Stock
According to Spark, TipRanks’ AI Analyst, RAPP is a Neutral.
Rapport Therapeutics, Inc. faces significant challenges with no revenue and substantial operational losses despite strong equity financing and low leverage. Technical indicators point to a downward trend, and valuation is difficult to ascertain. Positive clinical trial results offer some optimism, but leadership changes contribute to uncertainty.
To see Spark’s full report on RAPP stock, click here.
More about Rapport Therapeutics, Inc.
Average Trading Volume: 426,466
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.15B
Find detailed analytics on RAPP stock on TipRanks’ Stock Analysis page.